Analyst Price Target is $27.00
▲ +37.61% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Enliven Therapeutics in the last 3 months. The average price target is $27.00, with a high forecast of $27.00 and a low forecast of $27.00. The average price target represents a 37.61% upside from the last price of $19.62.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Enliven Therapeutics.